Tieton Capital Management LLC Purchases New Position in Niagen Bioscience, Inc. $NAGE

Tieton Capital Management LLC purchased a new position in Niagen Bioscience, Inc. (NASDAQ:NAGE) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,008,470 shares of the company’s stock, valued at approximately $6,407,000. Niagen Bioscience accounts for about 1.8% of Tieton Capital Management LLC’s investment portfolio, making the stock its 23rd biggest holding. Tieton Capital Management LLC owned 2.52% of Niagen Bioscience at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. JPMorgan Chase & Co. acquired a new stake in Niagen Bioscience in the third quarter valued at approximately $3,678,000. Vanguard Group Inc. acquired a new position in shares of Niagen Bioscience during the 3rd quarter worth approximately $37,522,000. Ameritas Investment Partners Inc. purchased a new position in shares of Niagen Bioscience during the 3rd quarter valued at approximately $45,000. Intech Investment Management LLC purchased a new position in shares of Niagen Bioscience during the 3rd quarter valued at approximately $202,000. Finally, Quantbot Technologies LP acquired a new stake in Niagen Bioscience in the 3rd quarter valued at $48,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Analysts Set New Price Targets

NAGE has been the subject of several recent analyst reports. Freedom Capital raised shares of Niagen Bioscience to a “strong-buy” rating in a report on Monday, July 6th. Wall Street Zen downgraded shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, August 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research note on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $10.33.

Niagen Bioscience Stock Performance

Shares of NAGE opened at $3.17 on Thursday. The stock has a 50 day moving average price of $3.31 and a 200 day moving average price of $4.13. Niagen Bioscience, Inc. has a one year low of $2.87 and a one year high of $10.52. The stock has a market capitalization of $252.46 million, a price-to-earnings ratio of 17.61 and a beta of 2.09.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. Niagen Bioscience had a return on equity of 17.95% and a net margin of 12.39%.The company had revenue of $29.78 million for the quarter, compared to analyst estimates of $29.95 million. On average, analysts predict that Niagen Bioscience, Inc. will post 0.13 earnings per share for the current year.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.